Omid Farokhzad

Omid Farokhzad

Chair & Chief Executive Officer

Omid Farokhzad

Chair & Chief Executive Officer

Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 175 papers and is an inventor of over 200 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.
Chairman of the Board
Catherine Friedman

Catherine Friedman

Retired Managing Director at Morgan Stanley

Catherine Friedman

Retired Managing Director at Morgan Stanley

Catherine Friedman held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including Managing Director, Head of West Coast Healthcare, and Co-Head of the Biotechnology Practice. She currently serves as the Chair of the Board of Directors of GRAIL, and is a member of the boards of directors of Altaba (formerly Yahoo!), Radius Health, and Lyell Immunopharma. She additionally serves as a trustee of The Darden School Foundation at the University of Virginia. She holds a B.A. in Economics from Harvard University and an M.B.A. from The University of Virginia’s Darden School of Business.
Independent Director
Meeta Gulyani

Meeta Gulyani

Head of Strategy, Business Development and Transformation at Millipore Sigma

Meeta Gulyani

Head of Strategy, Business Development and Transformation at Millipore Sigma

Meeta Gulyani is head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada. In this role, she leads the development of the sector strategy and strategic planning process across the organization. She also searches out and delivers deals of value to enable the achievement of the life science strategy and growth ambition. Meeta was previously Executive Vice President and Head of Strategy and Global Franchises for the biopharma business of Merck KGaA, Darmstadt, Germany. In this role, she was responsible for global business franchises, including Oncology, Neurology, Fertility, General Medicine & Endocrinology and Medical Devices, as well as key global functions. Prior to joining the company, Gulyani served as general manager for South Asia at Roche, and before that as Vice President, Head of Global Portfolio Management at Roche. Prior to Roche, she held several marketing and sales leadership positions of increasing responsibility within Sanofi-Aventis’s global and U.S. organizations. Gulyani also served as a strategy consultant with the Monitor Consulting Group based in Hong Kong and the United States. Meeta holds a Master of Business Administration from the Asian Institute of Management, Philippines, accompanied by an exchange program at the Wharton School of the University of Pennsylvania. She also earned a bachelor’s degree in economics from the Shri Ram College of Commerce at Delhi University in India.
Independent Director
David Hallal

David Hallal

Former Chief Executive Officer at Alexion Pharmaceuticals

David Hallal

Former Chief Executive Officer at Alexion Pharmaceuticals

David Hallal is CEO, Chairman and Co-Founder at ElevateBio, as well as CEO and Chairman at AlloVir, and ElevateBio company. He is also Chairman of the Board of Directors at the biotechnology companies iTeos Therapeutics and Scholar Rock. Prior to his roles at iTeos and Scholar Rock, David was Chief Executive Officer of Alexion Pharmaceuticals, which he first joined in 2006. In addition to his CEO role, David also served as Board member, Chief Operating Officer, Chief Commercial Officer and Head of Commercial Operations. Before joining Alexion, David served as Vice President of Sales for OSI Eyetech from 2004 to 2006. He served as Head of Sales at Biogen from 2002 to 2004, and before that, he was at a variety of leadership roles at Amgen from 1992 to 2002. David began his pharmaceutical career at The Upjohn Company, where he was a sales representative from 1998 to 1992. He has a B.A. in psychology from the University of New Hampshire.
Independent Director
Rachel Haurwitz, Ph.D. headshot

Rachel Haurwitz, Ph.D.

CEO at Caribou Biosciences, Inc.

Rachel Haurwitz, Ph.D.

CEO at Caribou Biosciences, Inc.

Rachel Haurwitz is a co-founder of Caribou Biosciences and has been its President and Chief Executive Officer and a director since the company’s inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors of the Biotechnology Organization (BIO). Rachel earned an A.B. in Biological Sciences from Harvard College and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Independent Director
Robert Langer, Sc.D.

Robert Langer, Sc.D.

Co-Chairman of Scientific Advisory Board

Robert Langer, Sc.D.

Co-Chairman of Scientific Advisory Board

Dr. Langer is the Chair of Seer’s Scientific Advisory Board. He is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 275,000 times with an H-Index of 262, and his inventions include over 1300 issued or pending patents. He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine). He is one of 4 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards. He served as a member of the U.S. FDA’s Science Board from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 26 companies, including Moderna, Momenta, and Transform. Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.
Terry McGuire

Terry McGuire

Founding Partner of Polaris Partners

Terry McGuire

Founding Partner of Polaris Partners

Terry McGuire is Founding Partner of Polaris Partners. As a venture capitalist, he has invested in more than 50 companies, and has also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkemes) and MicroCHIPS (private). Companies that Terry has supported have raised over $6 billion in equity and corporate capital. In 2013, Terry was listed as one of Forbes’ Top Life Sciences Investors, and in 2011, he was listed in Forbes’ Midas 100 List of Top Tech Investors. He currently chairs the Board of the Thayer School for Engineering, Dartmouth College, and serves on the Boards of the David Koch Institute for Integrative Cancer Research, the Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and the Healthcare Initiative Advisory Board (HBS). Terry has a BS in physics and economics from Hobart College, an MS in engineering from The Thayer School at Dartmouth College, and an MBA from Harvard Business School.
Independent Director
Deep Nishar

Deep Nishar

Senior Managing Partner at SoftBank Investment Advisers

Deep Nishar

Senior Managing Partner at SoftBank Investment Advisers

Deep Nishar is a Senior Managing Partner at SoftBank Investment Advisers (SBIA) in Silicon Valley. He leads the fund's investments in frontier tech, life sciences and enterprise software. Deep has more than 20 years of experience in helping build and grow software and internet businesses. Prior to joining SoftBank, Deep served as Senior Vice President of Products and User Experience at LinkedIn. He also held senior executive roles at Google, and was previously the Founder of enterprise software company Patkai Networks. He currently sits on the board of directors of 8 companies, including Relay Therapeutics, Inc. and Vir Bio, Inc.. Deep holds an MBA from Harvard Business School where he graduated as a Baker Scholar; an MSEE from the University of Illinois at Urbana-Champaign; and a Bachelor of Technology with honors from the Indian Institutes of Technology, Kharagpur. Deep has co-authored 14 patents, and is a recipient of the Google Founders Award which is given to employees who made extraordinary contributions to the company.
Independent Director
Omead Ostadan

Omead Ostadan

President & Chief Operating Officer

Omead Ostadan

President & Chief Operating Officer

Omead Ostadan is the President and Chief Operating Officer for Seer, as well as a member of our Board of Directors. He was most recently Chief Product and Marketing Officer and a member of Illumina’s executive management team. He joined Illumina in 2007 as Vice President of Marketing and built the company’s marketing organization during a period of tremendous growth and diversification. In 2011 Mr. Ostadan was Senior Vice President of Product Development and in 2015 his role expanded to include the company’s Global Operations and Quality functions. Prior to joining Illumina, Mr. Ostadan was Vice President of Marketing at Solexa from 2005-2007. Before Solexa, Mr. Ostadan held a variety of marketing roles at Applied Biosystems over a nearly 10-year span, where he managed the company’s high throughput sequencing platforms. Mr. Ostadan holds a BS in Biochemistry from the University of California at Davis and an MBA from The Wharton School at the University of Pennsylvania.
Ronaghi

Mostafa Ronaghi, Ph.D

Co-Chairman of Scientific Advisory Board, Chair of Technology Committee and Board Director

Mostafa Ronaghi, Ph.D

Co-Chairman of Scientific Advisory Board, Chair of Technology Committee and Board Director

Dr. Ronaghi is Board Member, Co-Chairman of the Scientific Advisory Board & Chair of the Technology Committee for Seer. He most recently spent over a decade at Illumina as Senior Vice President and Chief Technology Officer, where led internal research and technology development, co-founded Grail, and founded the Illumina Accelerator program, a first of its kind innovation ecosystem in the genomics industry. Before joining Illumina, he founded four life sciences companies – Avantome (acquired by Illumina in 2008); NextBio (acquired by Illumina in 2013); ParAllele Bioscience (acquired by Affymetrix in 2005); and Pyrosequencing AB (renamed as Biotage in 2003). Dr. Ronaghi was a principal investigator at the Stanford Genome Technology Center at Stanford University from 2002 to 2008, where his research focused on the development of novel molecular diagnostic tools and applications. He is the inventor of more than 30 patents and the author of more than 80 publications. Dr. Ronaghi received his B.Sc. in biochemistry from Kalmar University and his Ph.D. in biotechnology from the Royal Institute of Technology in Sweden.

Search Investor Relations